

Attorney Docket No.: 5958-US-DIV[2]

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Udagawa et al. Confirmation No: 5785

Serial No.: 10/849,106 Group Art Unit: 1656

Filed: May 19, 2004 Examiner: Nashaat Nashed

For: Lysophospholipase

**REQUEST FOR CORRECTED FILING RECEIPT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This application was filed on May 19, 2004 as a divisional of U.S. Application No. 10/309,437 filed December 4, 2002, which is a divisional of U.S. application no. 09/687,538 filed October 13, 2000, which claims priority or the benefit of Danish application no. PA 1999 01473 filed October 14, 1999 and U.S. provisional application no. 60/160,572 filed October 20, 1999.

The application and the Application Data Sheet submitted by Applicants incorrectly provided that U.S. application no. 09/687,538 is a continuation of U.S. application no. 09/678,513. Thus, the domestic priority data provided in the Filing Receipt mailed October 7, 2004 is incorrect.

Applicants therefore request the issuance of a corrected filing receipt with correct domestic priority data. An Amendment correcting the Cross-Reference to Related Applications section and a Supplemental Application Data Sheet providing the correct domestic priority data are submitted herewith.

All required fees were charged to Novozymes North America, Inc.'s Deposit Account No. 50-1701 at the time of electronic filing. The USPTO is authorized to charge this Deposit Account should any additional fees be due.

Respectfully submitted,

Date: September 20, 2011

/Elias Lambiris, Reg. # 33728/  
Elias J. Lambiris, Reg. No. 33,728  
Novozymes North America, Inc.  
500 Fifth Avenue, Suite 1600  
New York, NY 10110  
(919) 494-3405

---